Candelaria Gomez-Manzano

This inventor holds 9 USPTO granted patents and 7 published patent applications and 3 EPO patents. Top assignees: The University of Texas System, Dnatrix, Inc., Regeneron Pharmaceuticals, Inc.. Active years: 2008-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Candelaria Gomez-Manzano. Retrieved from https://idiyas.com/inventor/candelaria-gomez-manzano

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 7)

% Patents Active = 66.7

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 4.3

ph-index = 5

Forward Citations = 51(Granted Patents)

Company Filing History:

7 out of 5,640

The University of Texas System

Regeneron Pharmaceuticals, Inc.

patents

4. 1 out of 641

The UAB Research Foundation (The University of Alabama at Birmingham)

patents

5. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2008-2021

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11155599 - Adenoviruses expressing heterologous tumor-associated antigens (2021-10-26),

2. 11090344 - Adenovirus and immunomodulator combination therapy (2021-08-17),

3. 11065285 - Biomarkers and combination therapies using oncolytic virus and immunomodulation (2021-07-20),

4. 10391183 - Infectivity-enhanced conditionally-replicative adenovirus and uses thereof (2019-08-27),

5. 10238698 - Biomarkers and combination therapies using oncolytic virus and immunomodulation (2019-03-26),

6. 10080774 - Oncolytic adenovirus armed with therapeutic genes (2018-09-25),

7. 9061055 - Oncolytic adenovirus armed with therapeutic genes (2015-06-23),

8. 8168168 - Infectivity-enhanced conditionally-replicative adenovirus and uses thereof (2012-05-01),

9. 7354582 - Use of VEGF antagonists for the treatment of malignant gliomas (2008-04-08),

Title: Candelaria Gomez-Manzano: Innovator in Cancer Therapy

Introduction

Candelaria Gomez-Manzano is a prominent inventor based in Houston, TX, known for her significant contributions to cancer therapy. With a total of nine patents to her name, she has made remarkable strides in the field of medical innovation.

Latest Patents

Her latest patents include "Adenoviruses expressing heterologous tumor-associated antigens," which focuses on adenoviruses designed for cancer therapy. This invention involves adenoviruses that incorporate one or more heterologous nucleic acid sequences encoding a tumor antigen, allowing the adenovirus to express tumor antigens on its surface. Another notable patent is "Adenovirus and immunomodulator combination therapy," which aims to enhance the effectiveness of adenoviral cancer therapies.

Career Highlights

Candelaria has worked with esteemed organizations such as the University of Texas System and Dnatrix, Inc. Her work has been pivotal in advancing cancer treatment methodologies, showcasing her dedication to improving patient outcomes.

Collaborations

Throughout her career, Candelaria has collaborated with notable professionals, including W K Alfred Yung and Charles A Conrad. These partnerships have further enriched her research and development efforts in the field of oncology.

Conclusion

Candelaria Gomez-Manzano's innovative work in cancer therapy exemplifies her commitment to advancing medical science. Her patents and collaborations highlight her role as a leading inventor in the fight against cancer.

Profile summary based on public USPTO records.